Fludarabine (NSC 118218)

For research use only. Not for use in humans.

製品コードS1491 別名：FaraA, Fludarabinum

CAS No. 21679-14-1

Fludarabine (NSC 118218, FaraA, Fludarabinum) is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells. Fludarabine induces apoptosis.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 22900
10mg	JPY 18100
50mg	JPY 53400
200mg	JPY 130160

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(103)

製品安全説明書

STAT阻害剤の選択性比較

生物活性

製品説明

ターゲット

STAT1 ^[4]
(Vascular smooth muscle cells)

体外試験

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. ^[1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. ^[2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. ^[3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. ^[4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. ^[5]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Jeko-1	NGDBdHRHfW6ldHnvckBCe3OjeR?=	NHzEd4UzOCEQvF2=	NWLzUGE1OjRiaB?=		NVPzWVhvcW6qaXLpeJMh\XiycnXzd4lwdiCxZjDJSG8>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2MEexNkc,OjV7NEC3NVI9N2F-
MV-4-11	NHv0[pRCeG:ydH;zbZMhSXO\|YYm=	NFrxbG8zNjVizszN	NVXKb3dWPDhiaB?=		NXfxUJFocW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk>	NVrkeIc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNVE2QDNpPkK1NVEyPTh\|PD;hQi=>
THP-1	M{G5NWFxd3C2b4Ppd{BCe3OjeR?=	M4j0fFIvPSEQvF2=	NX;3TVVoPDhiaB?=		M{TpXYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	MkC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMUG1PFMoRjJ3MUGxOVg{RC:jPh?=
MOLM 13	NIPFe4tCeG:ydH;zbZMhSXO\|YYm=	MnLwNk42KM7:TR?=	MVq0PEBp		NEDUbJFqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFzMUW4N{c,OjVzMUG1PFM9N2F-
KBM3/Bu2506	MV\BdI9xfG:\|aYOgRZN{[Xl?	NH;TPW4zNjVizszN	NHjoeJM1QCCq		MWrpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	NV3XVVlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNVE2QDNpPkK1NVEyPTh\|PD;hQi=>
Nalm-6	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\ZTWM2OD1zODFOwG0>	MoewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
Reh	NIDUenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHYTWM2OD1\|MDFOwG0>	NEPtNFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVExOSd-MkWwOlEyODF:L3G+
U2937	NY\3[JVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37CV2lEPTB;MU[g{txO	NXLoSZJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlEyODFpPkK1NFYyOTBzPD;hQi=>
Mec-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|Ux97zgNUCwJO69VQ>?	NYfyTnFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlEyODFpPkK1NFYyOTBzPD;hQi=>
RPMI-8226	M1f0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzoXmlsUUN3ME21NFAh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
Molt-4	MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlO3TWM2OD1zOECg{txO	MofaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
Nalm-6-FluR	NX\1TIV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;abZdKSzVyPUK1NEDPxE1?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
Raji	Ml3rSpVv[3Srb36gRZN{[Xl?	NIfRXHQ{yqEQvF2=	NVLv[HFGOjRxNEivO\|IhcA>?		M4rNUolv\HWlZYOgZYNkfW23bHH0bY9veyCxZjDwOVMtKHB4MzDhcoQheDd\|wrC=	NI\UZpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0NFY6PSd-MkS5OFA3QTV:L3G+
PBMC	NGGxfoZHfW6ldHnvckBCe3OjeR?=	M{PmfFUxNzFyMDFOwG0>	MYiyOEBp	MULEUXNQ	NXjM[m82cW6qaXLpeJMhW1SDVEGgdIhwe3Cqb4L5cIF1cW:w	NH;DbXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVg4Oid-MkS5NVE5PzJ:L3G+
MDA-231	M1XZNWZ2dmO2aX;uJGF{e2G7	NIf2V5oyODBizszN	MkDuNlQhcA>?	NY[4[lhSTE2VTx?=	M1HM[oRm[3KnYYPld{BKTE9iZYjwdoV{e2mxbh?=	NGLLT2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVg4Oid-MkS5NVE5PzJ:L3G+
624.38mel	MV;GeY5kfGmxbjDBd5NigQ>?	M2faTlUxKM7:TR?=	M2PqclI1KGh?	M2myNWROW09?	NYTrOGNb\GWlcnXhd4V{KEmGTzDlfJBz\XO\|aX;u	NWLXUpB1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVE5PzJpPkK0PVEyQDd{PD;hQi=>
MDA-231	MXLGeY5kfGmxbjDBd5NigQ>?	M1XsZlUxNTJyMDFOwG0>	NFH6OGYzPCCq	NEjQ[VJFVVOR	NFTZR5FqdmirYnn0d{BKTE9iYXP0bZZqfHliaX7k[ZBmdmSnboTsfUBw\iCvUl7BJIxmfmWucx?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzMUi3Nkc,OjR7MUG4O\|I9N2F-
624.38mel	MW\GeY5kfGmxbjDBd5NigQ>?	NIjLOlE2OC1{MECg{txO	NYrkdWhyOjRiaB?=	NWDYXI9kTE2VTx?=	MYPpcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>?	MmHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUG4O\|IoRjJ2OUGxPFczRC:jPh?=
HMECs	NH3oO5VHfW6ldHnvckBCe3OjeR?=	MVKxNFDDqM7:TdMg	M4L6d\|M3yqCq		NWLocVdmcW6qaXLpeJMhUU[QzsRCpIFv\CCOUGOgbY5lfWOnZDDTWGFVOSCyaH;zdIhwenmuYYTpc44h[W6mIFnSSlEh\XiycnXzd4lwdg>?	NYTZPZQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNVE{OjdpPkK0NlEyOzJ5PD;hQi=>
HMECs	M4m1SGZ2dmO2aX;uJGF{e2G7	M{TUdVExOMLizszNxsA>	M2XkcFM3yqCq		NEniW25qdmirYnn0d{BKTk8QsdMgcYVlcWG2ZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHNVSVRzIHHu[EBUXEGWMzygZpV1KG6xdDDv[kBUXEGWMh?=	M37UclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxN\|I4Lz5{NEKxNVMzPzxxYU6=
BJAB	NXLtNFFwSXCxcITvd4l{KEG\|c3H5	NVrrbGNrPcLizszN	NEPKfpczPCCq		Moj3bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB3N{G0O{c,OjRyNUexOFc9N2F-
I-83	NEfZZVhCeG:ydH;zbZMhSXO\|YYm=	NHOyWIc2yqEQvF2=	MnjCNlQhcA>?		MVLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB3N{G0O{c,OjRyNUexOFc9N2F-
NALM6	NVr3cXZUSXCxcITvd4l{KEG\|c3H5	NFHKPWY2yqEQvF2=	NYrSSFFROjRiaB?=		NXLI[XhNcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NG\RNFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC1O\|E1Pyd-MkSwOVcyPDd:L3G+
DU-145	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVywMVExKM7:Zz;tcC=>	NVfGU\|lXPDhiaNMg		M1G2T4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd\|NEixOUc,OjN5M{S4NVU9N2F-
Nalm-6	NELSWJpHfW6ldHnvckBCe3OjeR?=	MmO3NVDDqM7:TR?=	MoW4NU8zNzRiaB?=		NV3iR\|BNcW6mdXPld{BifXSxcHjh[5k>	MortQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEGyNlMoRjJ\|NkixNlI{RC:jPh?=
Reh	M4LwTGZ2dmO2aX;uJGF{e2G7	MlnYNVDDqM7:TR?=	NXiwepZvOS9{L{SgbC=>		M3zXTYlv\HWlZYOgZZV1d3CqYXf5	M2TL[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkixNlI{Lz5{M{[4NVIzOzxxYU6=
Nalm-6	NXX4dFRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE[zS2lKSzVyIPMIwFEx6oDLzszN	NWfk[WNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFEzOjNpPkKzOlgyOjJ\|PD;hQi=>
Reh	MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3hPIExUUN3MDFijNwyOOLCid88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MUKyN{c,OjN4OEGyNlM9N2F-
HEC1A	Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVuxNFAuPTByIN88US=>	MU[yOEBp		NUHvO2xqcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NYfnWoRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
AN3CA	Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\wWmYxOTByLUWwNEDPxE1?	NIXyV5AzPCCq		MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NVzk[JVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
HEC50B	M3nzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3hPWIyODBvNUCwJO69VQ>?	NHXoflczPCCq		NH7yWW9qdmirYnn0d{Bk\WyuIHfyc5d1cCC\|bHnnbJRtgQ>?	NF[5VmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5OVY6Pyd-MkO1PVU3QTd:L3G+
HEC1A	NGixS3lCeG:ydH;zbZMhSXO\|YYm=	MlXCNlAwOTByIN88US=>	NGKyc\|YzPCCq		MmnmbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NGDDeI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5OVY6Pyd-MkO1PVU3QTd:L3G+
AN3CA	MV\BdI9xfG:\|aYOgRZN{[Xl?	NXXlTVVXOjBxMUCwJO69VQ>?	NILx[m4zPCCq		NEC1U3lqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
HEC50B	MUfBdI9xfG:\|aYOgRZN{[Xl?	MVqyNE8yODBizszN	MnS2NlQhcA>?		MlrFbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	Mn70QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OUW2PVcoRjJ\|NUm1Olk4RC:jPh?=
EHEB	MUjBdI9xfG:\|aYOgRZN{[Xl?	MUO0NEDPxE1?	MnfTNlQhcA>?		MWXpcoR2[2W\|IHHwc5B1d3Orcx?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{C3OUc,OjN2OUewO\|U9N2F-
A549	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTF3LkhCtVIvQCEEtV2=	Mnz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|N{exPVIoRjJ\|M{e3NVkzRC:jPh?=
A549 GAPDH-deficient	NXL6O3RoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDLTWM2OD1zOD61xtEzNjNiwsXN	NFzYVos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O3O\|E6Oid-MkOzO\|cyQTJ:L3G+
CLL	M3\sdmFxd3C2b4Ppd{BCe3OjeR?=	MYmxNEDPxE4EoB?=	Ml;oNlQuQTZiaB?=		M3nOd4lv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg>	NX36Omo2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNFc3QDZpPkKyNlA4Pjh4PD;hQi=>
MEC1	MVHBdI9xfG:\|aYOgRZN{[Xl?	MV:xNFDDqM7:TR?=	NFjUcm04OiCq		MorCbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	NU\jVGM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxN\|I6PzNpPkKyNVMzQTd\|PD;hQi=>
U937	M{XHfmFxd3C2b4Ppd{BCe3OjeR?=	NWrMOFZIOC56IN88US=>	NHf1[pM1NTR6IHi=		MlzpbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	M1ToSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe0O\|AxLz5{MkC3OFcxODxxYU6=
U937	MlHKRZBweHSxc3nzJGF{e2G7	MWqxJO69VQ>?	Mmj1PVYhcA>?		M3rXTolv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	M4HKSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEKzOVI{Lz5{MkCyN\|UzOzxxYU6=
Daudi	MXPBdI9xfG:\|aYOgRZN{[Xl?	MmrLNlAh\|ryP	MUO5OkBp		M3jOeIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	NGnDOos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyN\|UzOyd-MkKwNlM2OjN:L3G+
J45.01	MU\BdI9xfG:\|aYOgRZN{[Xl?	NXzGc21OOSEQvF2=	NHrDSHk6PiCq		MljDbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{M{WyN{c,OjJyMkO1NlM9N2F-
RPMI 8226	Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYS1cYRRUUN3ME2yOU46yqEEsdMgN{44KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
CEM	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTJwNNMgxtHDqDBwNDFOwG0>	NVzCU\|g6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFgzPjRpPkKxPVQ5OjZ2PD;hQi=>
Raji	MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXHTWM2OD1yLkS3xsDDucLiMD6wOEDPxE1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
U937	M{\QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWP2XWJVUUN3ME2wMlI1yqEEsdMgNE4xPCEQvF2=	NHK1OoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0PFI3PCd-MkG5OFgzPjR:L3G+
K562	MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTBwNEVCpOKyyqByLkC1JO69VQ>?	NETqN289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0PFI3PCd-MkG5OFgzPjR:L3G+
NALM-6	M1\KbGFxd3C2b4Ppd{BCe3OjeR?=	NE\FNGoyOCEQvF5CpC=>	MVSyOEBp		MVLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KHOuaXfoeIx6	MlSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4OUmzPFMoRjJzNkm5N\|g{RC:jPh?=
JMV-3	NHeydnBCeG:ydH;zbZMhSXO\|YYm=	NX7K[m9xOTBizszNxsA>	MX6yOEBp		NUn1NVRqcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?=	NVS2UnZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2PVk{QDNpPkKxOlk6Ozh\|PD;hQi=>
EHEB	M4e0bWZ2dmO2aX;uJGF{e2G7	NX32ToFDPS13MDFOwG0>	NVXoUWhHOjRiaB?=		NUDUS5gz\GWlcnXhd4V{KHB{MTDlfJBz\XO\|aX;uJJNq\26rZnnjZY51dHl?	NFrWdY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG2PFM6OSd-MkGxOlg{QTF:L3G+
JVM-2	MYPGeY5kfGmxbjDBd5NigQ>?	M{XhUFMxKM7:TR?=	NWnsXmZsOjRiaB?=		MXnk[YNz\WG\|ZYOgdFIyKGW6cILld5Nqd25?	NX3JZWU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxOlg{QTFpPkKxNVY5OzlzPD;hQi=>
KBM3/Bu2506	NXHsSpNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;3dHdKSzJyPUCuOlchyrWP	NH;mRYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEmzN\|UxQSd-MkC5N\|M2ODl:L3G+
KBM3/Bu2506	MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWSwMlYh\|ryP	NEftW\|AzPCCq		MX7pcoNz\WG\|ZYOgeIhmKGOnbHyg[pJi[3Srb36gbY4hWy2yaHHz[S=>	MlqxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7M{O1NFkoRjJyOUOzOVA6RC:jPh?=
MDA-MB-231	MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTRwMDFOwG0>	M{O2N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNES3N\|kxLz5{MES0O\|M6ODxxYU6=
MCF-7	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvtNpFKSzVyPUG1MlAh\|ryP	NVjSTZJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OFc{QTBpPkKwOFQ4OzlyPD;hQi=>
HLE-B3	NVfFTVlCTnWwY4Tpc44hSXO\|YYm=	NVvBWFlCOjVizszN	M{HWWlQ5KGh?		MVHicI9kc3NiSV\OMe6{6oDVaX7keYNm\CCVVFHUNUBxcG:\|cHjvdplt[XSrb36gZY5lKEmGTzDlfJBz\XO\|aX;u	MnqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2M{WxOVgoRjJyNEO1NVU5RC:jPh?=
K562	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlrMO\|IhcA>?		Mmq0TWM2OD1\|LkOgcm0>	M2fKcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{C3NVk5Lz5{MEOwO\|E6QDxxYU6=
BW-225	M4j4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUL4fHU1UUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=>	MoTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NkGzPFAoRjF6Nk[xN\|gxRC:jPh?=
OH-65	MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrPOJhIUUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=>	MoG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NkGzPFAoRjF6Nk[xN\|gxRC:jPh?=
GR-145	NHnnRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfzUJhIUUN{ME2yMlc1KMPZIEGw5qiTQCBizszNxsA>	NX;WTHJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OlE{QDBpPkG4OlYyOzhyPD;hQi=>
A549	NGjZ[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1n4ZWlEOjB;NT60PEDEnyBzMPMIllgh\|ryPwrC=	NF7KVXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[2NVM5OCd-MUi2OlE{QDB:L3G+
CaSki	NEfnbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGL0WZhKSzJyPUGuN\|chy5diMUFijLI4KM7:TdMg	NVrKO41ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OlE{QDBpPkG4OlYyOzhyPD;hQi=>
ZMK-1	NIHx[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|IxRTFwM{egx7chOTEkiKK2JO69VcLi	NVzNZ5pWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OlE{QDBpPkG4OlYyOzhyPD;hQi=>
SKW6.4	MYnBdI9xfG:\|aYOgRZN{[Xl?	M4fGNVAvODFvMUCg{txO	M{LXbVI1NzR6IHi=		NH;hbZlqdmS3Y3XzJINmdGxiZHXheIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT2g[IVx\W6mZX70JI1idm6nch?=	NES5O4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC5NlM1OCd-MUiwPVI{PDB:L3G+
RPMI 8226	NFfvdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkL2NlQhcA>?		NFPTTWZKSzVyPUGuOVTDqM7:TR?=	M1q0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUe2NVg3Lz5zN{m3OlE5PjxxYU6=
MM.1S	NIHzNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVHCe5MxPDhiaB?=		M3LGZ2lEPTB;MUOuOFjDqM7:TR?=	M3PwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUe2NVg3Lz5zN{m3OlE5PjxxYU6=
MM.1R	NEfsUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mo\LOFghcA>?		NUXRfHpNUUN3ME2zN{44QSEQvF2=	NI[2[Yw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m3OlE5Pid-MUe5O\|YyQDZ:L3G+
U937	MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDQdIJKSzVyPUOsNlAxKMLzIEW2NEBvVQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTl\|MEO2NUc,OTV7M{CzOlE9N2F-
CLL5	M3vBW2FvfGm2dX3vdkBie3OjeR?=		NFHLR3I1QCCqcoO=		MYPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDDUGw2KGOnbHzzJIl{d2yjdHXkJIZzd21iQ1zMJJBifGmnboSgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IF\BR3Mh[W6jbInzbZMtKEWFNUCgQUAxNjF4IN88UU4>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5M{ezPUc,OjR4N{O3N\|k9N2F-
K562	MnzwR5l1d3SxeHnjbZR6KGG\|c3H5		M1;WUFczKGi{cx?=		NVrNcIJpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4heGGlbHn0ZZhmdC2{ZYPpd5RidnRiS{W2NkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6yOkDPxE1w	MnfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MEW2OVYoRjJyNkC1OlU3RC:jPh?=
CLL3	MnHkRY51cXS3bX;yJIF{e2G7		NXzmcpc6PDhiaILz		NITOV45CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBEVEx\|IHPlcIx{KGm\|b3zheIVlKG[{b32gR2xNKHCjdHnlcpQh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JGZCS1NiYX7hcJl{cXNuIFXDOVAhRSByLkO1JO69VS5?	MkCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N\|koRjJ2NkezO\|M6RC:jPh?=
CLL4	NFzqd3ZCdnSrdIXtc5Ih[XO\|YYm=		NWLDWWx[PDhiaILz		MlXNRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNPCClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOC54NDFOwG0v	MoXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N\|koRjJ2NkezO\|M6RC:jPh?=
CEM-DNR-B	Mmn1R5l1d3SxeHnjbZR6KGG\|c3H5		MkHJO\|IhcHK\|		NUP1UFlHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0WPLVTOVk1DKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlAyKM7:TT6=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZyNU[1Okc,OjB4MEW2OVY9N2F-
primary CLL	Mnn5R5l1d3SxeHnjbZR6KGG\|c3H5				MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDwdolu[XK7IFPMUEBk\WyuczygUGQ2OCB;IEGuNUDPxE1w	NXXDenFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOFg{QTJpPkK1NVQ5Ozl{PD;hQi=>
CLL6	M2SxeWFvfGm2dX3vdkBie3OjeR?=		NWfPcmhNPDhiaILz		M3iwOGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDZiY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDFwNjFOwG0v	M3nYWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
CLL2	MWPBcpRqfHWvb4KgZZN{[Xl?		MnTUOFghcHK\|		MmX0RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNOiClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOi54NjFOwG0v	NUTqe5lWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
HCT116	Mn;qR5l1d3SxeHnjbZR6KGG\|c3H5		M1TRUFczKGi{cx?=		MlfmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA3NjZizszNMi=>	M4nCclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlc4Lz5{NUS2NlI4PzxxYU6=
PBMC	NV\Cc2N6S3m2b4TvfIlkcXS7IHHzd4F6		M4C3OlQ5KGi{cx?=		M1r3[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHCjdHnlcpQhWEKPQzDh[pRmeiB2ODDodpMh[nliQ3XscHRqfHKnLVLseYUh[XO\|YYmgbY4heHKnc3XuZ{Bw\iCvb4Xz[UBOOjFyQkSgZ4VtdHNuIFnDOVAhRSBzMDFOwG0v	M1naUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[yOFE4Lz5{NUW2NlQyPzxxYU6=
CHO	NF\SN\|VHfW6ldHnvckBie3OjeR?=				NXrNb3h3SmmwZHnu[{Bi\m[rbnn0fUBl\XSncn3pcoVlKGK7IHTpd5Bt[WOnbXXueEBw\iC\|cHXjbYZq[yCkaX7kbY5oKG:oIGuxNlVKZU5vKEStZY1qdm9vMz3pc4RweGinbnX0bJltMS2jZHXuc5NqdmViaX6gcYVu[nKjbnXzJI9nKEOKTzDj[YxteyC\|dHHicJkhfHKjboPm[YN1\WRid3n0bEB1cGVicnH0JIFl\W6xc3nu[UBCOyC{ZXPldJRweixiS3mgQUAyOC52IN88UU4>	M4XFWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd5MEezNlAoRjd5MEezNlA9N2F-
JVM2	M2PDbmFvfGm2dX3vdkBie3OjeR?=				MX7BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCMVl2yJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCIQVPTJIFv[Wy7c3nzMEBGSzVyIE2gNVAvPCEQvF2u	Moq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N\|koRjJ2NkezO\|M6RC:jPh?=
HeLa	M1n1NWFvfGm2dX3vdkBie3OjeR?=				NFnWNW5CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIJ6KE2WVDDhd5NigSxiRVO1NEA:KDF4IN88UU4>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5M{ezPUc,OjR4N{O3N\|k9N2F-
CLL1	Mmr0RY51cXS3bX;yJIF{e2G7		NH7aOZQ1QCCqcoO=		MnO5RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNOSClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOTdwMTFOwG0v	NUO3PIxiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
CEM	MoizR5l1d3SxeHnjbZR6KGG\|c3H5		NVf4fIJ5PzJiaILz		MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG5MlQ6KM7:TT6=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZyNU[1Okc,OjB4MEW2OVY9N2F-
T47D	NX;5XIpJS3m2b4TvfIlkcXS7IHHzd4F6		NIn5VFk4OiCqcoO=		NUD3U\|N2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXDR5RDDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hPDZwMjFOwG0v	MlPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkKyO\|coRjJ3NE[yNlc4RC:jPh?=
A549	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=		NIXNfIk4OiCqcoO=		MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0O{41PCEQvF2u	NF\Nbnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[wOVY2Pid-MkC2NFU3PTZ:L3G+
CCRF-CEM	NGDScGJHfW6ldHnvckBie3OjeR?=	M4r6R\|ExKHWP	MoLCNUB1dyB4MDDtbY5{		Ml7oSJJ2\yC2cnHud5BwenRiaX6gbJVu[W5iQ1PSSk1ETU1iY3XscJMh[XO\|ZYPz[YQh[XNiRV7UNU1u\WSrYYTl[EB2eHSja3WgZZQhOTBidV2gZYZ1\XJiMTD0c{A3OCCvaX7zJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6pIHHuZYx6e2m\|	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6OEewOUc,OjN\|OEi3NFU9N2F-
TC32	MorzdWhVWyCjc4PhfS=>				MoTXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	MVHxTHRUKGG\|c3H5				MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	M161[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MXTxTHRUKGG\|c3H5				NVT2Xo9SeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NEX3U2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	NHL4O2hyUFSVIHHzd4F6				M1nFeJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	NGPCWoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	MYXxTHRUKGG\|c3H5				MWDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NHXHWGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	MXvxTHRUKGG\|c3H5				MoG1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	NWLKU2FLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	Mon1dWhVWyCjc4PhfS=>				NYfsXmxzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	NWWwXVRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	Ml;RdWhVWyCjc4PhfS=>				MlzSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	M4TYOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NGTKWYRyUFSVIHHzd4F6				MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	MnjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	MlvsdWhVWyCjc4PhfS=>				NXj6b244eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	MnvPdWhVWyCjc4PhfS=>				MoPudWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NIHweYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	MnHZdWhVWyCjc4PhfS=>				MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	M1X5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	M{fvZZFJXFNiYYPzZZk>				MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0yOiClZXzsdy=>	MkDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NVzocpNZeUiWUzDhd5NigQ>?				NEHzbGpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>?	NWjFN2c4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	M17PbpFJXFNiYYPzZZk>				M13wUJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHN?	NWLB[pE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	MXzxTHRUKGG\|c3H5				NV7uTWtEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NGHJUJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NXPp[WJpeUiWUzDhd5NigQ>?				MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NHPEXlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	MUfxTHRUKGG\|c3H5				MnjVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	Ml;RdWhVWyCjc4PhfS=>				M3XXRZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	NWjxfoN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	MXPxTHRUKGG\|c3H5				MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	MmXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	NUHlSFNxeUiWUzDhd5NigQ>?				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	NX;4RWZKeUiWUzDhd5NigQ>?				MnfadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{	M1LKRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	NXj1WGN2eUiWUzDhd5NigQ>?				NW\qPGlNeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	MlnUdWhVWyCjc4PhfS=>				M4\XdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NV\VNYpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	MnnadWhVWyCjc4PhfS=>				M2DBTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJFKGOnbHzz	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Daoy	NWHYNYNOeUiWUzDhd5NigQ>?				MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJGRid3liY3XscJM>	Mom5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	MVPxTHRUKGG\|c3H5				MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGIHPhd5Bie2Vic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	MkDSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	NEnZUXByUFSVIHHzd4F6				NHrueI1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	NELzdWZyUFSVIHHzd4F6				NVnsd\|FieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NGjG[Zg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	M{XpWJFJXFNiYYPzZZk>				M3fpN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NVfzdIdneUiWUzDhd5NigQ>?				M13kUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NX[5eo1rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	M2DMdpFJXFNiYYPzZZk>				MkmzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NH;Nbos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	NXrD[YdyeUiWUzDhd5NigQ>?				NV6zV5E2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	MoPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	MY\xTHRUKGG\|c3H5				NG\1b4VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	MYfxTHRUKGG\|c3H5				MkfmdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	M4nhSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MV3xTHRUKGG\|c3H5				M{D1RZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	MlrhdWhVWyCjc4PhfS=>				MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{	MmS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	MlTIdWhVWyCjc4PhfS=>				MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	Mn3CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	M3TUN5FJXFNiYYPzZZk>				M2XCW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MUDxTHRUKGG\|c3H5				MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTZY9{NTJiY3XscJM>	Mk[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	M{fhS5FJXFNiYYPzZZk>				NXrue4Q2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	MoPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NI\NR3JyUFSVIHHzd4F6				NHr1O4pyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFKGIHPlcIx{	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	procaspase-9 / procaspase-3; PubMed: 27223263 Oncotarget Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control. p-p53 / p53; PubMed: 27223263 Oncotarget (A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒ STAT1; PubMed: 26677135 Int J Mol Med Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.	27223263 26677135
Immunofluorescence	α-SMA / Vimentin; PubMed: 28322315 Sci Rep FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).	28322315
Growth inhibition assay	Cell viability ; PubMed: 24956101 PLoS One CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.	24956101

体内試験

Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. ^[1]

お薦めの試験操作（参考用のみ）

細胞試験： ^[1]	- 合併細胞株： Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines 濃度： 2 μg/mL 反応時間： 24 hours 実験の流れ： After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 10⁵ cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit. (参考用のみ)
動物試験： ^[1]	- 合併動物モデル： Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells 投薬量： 40 mg/kg 投与方法： Administered via i.p. (参考用のみ)

細胞試験：

^[1]

- 合併

細胞株： Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
濃度： 2 μg/mL
反応時間： 24 hours
実験の流れ：
After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 10⁵ cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.

(参考用のみ)

動物試験：

^[1]

- 合併

動物モデル： Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
投薬量： 40 mg/kg
投与方法： Administered via i.p.
(参考用のみ)

参考

- 合併

溶解度 (25°C)

体外	DMSO	57 mg/mL (199.83 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O 混合させたのち直ちに使用することを推奨します。	8 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Fludarabine (NSC 118218) SDFをダウンロードする

分子量	285.23
化学式	C₁₀H₁₂FN₅O₄
CAS No.	21679-14-1
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	FaraA, Fludarabinum
Smiles	C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04526795	Not yet recruiting	Drug: Cytarabine\|Drug: Fludarabine\|Drug: Pegcrisantaspase	Blast Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent Acute Biphenotypic Leukemia\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent T-Cell Prolymphocytic Leukemia\|Refractory Acute Biphenotypic Leukemia\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Refractory T-Cell Prolymphocytic Leukemia	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	December 31 2020	Phase 1
NCT03832127	Not yet recruiting	Drug: 18F-Fludarabine	Myeloma	Nantes University Hospital\|Cyceron	April 1 2019	Phase 1
NCT03696537	Active not recruiting	Drug: Fludarabine\|Radiation: Total Marrow Irradiation (TMI)	Acute Myeloid Leukemia\|Chronic Myeloid Leukemia\|Acute Lymphocytic Leukemia\|Myelodysplastic Syndromes	Naoyuki G. Saito M.D. Ph.D.\|Indiana University	August 29 2018	Phase 1
NCT02718755	Withdrawn	Drug: Fludarabine\|Drug: Cytarabine\|Drug: Erwinase	Hematologic Malignancy	M.D. Anderson Cancer Center\|Jazz Pharmaceuticals	May 2018	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
how to re-suspend and deliver the inhibitor for in vivo experiments?
回答：
For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STATシグナル伝達経路

相関STAT製品

Cerdulatinib (PRT062070) hydrochloride

Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
FLLL32

FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.
S3I-201

S3I-201 (NSC 74859) shows potent inhibition of STAT3 DNA-binding activity with IC50 of 86 μM in cell-free assays, and low activity towards STAT1 and STAT5.

Features:A chemical probe inhibitor of Stat3 activity.
Cryptotanshinone

Cryptotanshinone is a STAT3 inhibitor with IC50 of 4.6 μM in a cell-free assay, strongly inhibits phosphorylation of STAT3 Tyr705, with a small effect on STAT3 Ser727, but none against STAT1 nor STAT5. Cryptotanshinone induces ROS-dependent autophagy and mitochondria-mediated apoptosis.
Niclosamide (BAY2353)

Niclosamide (BAY2353, Niclocide, NSC 178296) can inhibit DNA replication and inhibit STAT3 with IC50 of 0.7 μM in a cell-free assay. Niclosamide selectively inhibited the phosphorylation of STAT3 and had no obvious inhibition against the activation of other homologues (e.g., STAT1 and STAT5).
Stattic

Stattic, the first nonpeptidic small molecule, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM in cell-free assays, highly selectivity over STAT1. Stattic induces apoptosis.

Features:Stattic is the first non-peptide small molecule with inhibitory activity against STAT3 SH2 domain regardless of the STAT3 phosphorylation state in vitro.
Nifuroxazide

Nifuroxazide is a cell-permeable and orally available nitrofuran-based antidiarrheal agent that effectively suppresses the activation of cellular STAT1/3/5 transcription activity with IC50 of 3 μM against IL-6-induced STAT3 activation in U3A cells.

研究分野別

製品類型

Fludarabine (NSC 118218)

文献中Selleckの製品使用例(103)

製品安全説明書

STAT阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Fludarabine (NSC 118218) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技術サポート

よくある質問（FAQ）

STATシグナル伝達経路

相関STAT製品